NeuBase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

NeuBase Therapeutics

11/05/2023 22:37

* NeuBase Therapeutics Inc  NBSE.OQ  reported a quarterly
adjusted
loss of 12 cents​​ per share for the quarter ended in March. The
mean expectation of two analysts for the quarter was for a loss
of 11 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NeuBase Therapeutics Inc's reported EPS for the quarter
was a
loss of 12 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * NeuBase Therapeutics Inc shares had risen by 2.6% this
quarter and lost 0.2% so far this year.
    * The company reported a quarterly loss of $4.09 million.
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:37 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.11          -0.12          Missed
 Dec. 31 2022      -0.15          -0.11          Beat
 Sep. 30 2022      -0.28          -0.24          Beat
 Jun. 30 2022      -0.30          -0.26          Beat